Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade B 1.01 1.00% 0.01
ALIM closed up 1.0 percent on Friday, November 16, 2018, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Down Down
See historical ALIM trend table...

Date Alert Name Type % Chg
Nov 16 200 DMA Resistance Bearish 0.00%
Nov 16 20 DMA Resistance Bearish 0.00%
Nov 16 50 DMA Resistance Bearish 0.00%
Nov 16 180 Bearish Setup Bearish Swing Setup 0.00%
Nov 16 Narrow Range Bar Range Contraction 0.00%
Nov 16 NR7 Range Contraction 0.00%
Nov 16 NR7-2 Range Contraction 0.00%
Nov 16 Gapped Up Strength 0.00%
Nov 15 Narrow Range Bar Range Contraction 1.00%
Nov 15 NR7 Range Contraction 1.00%

Older signals for ALIM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.38
52 Week Low 0.74
Average Volume 99,091
200-Day Moving Average 1.0116
50-Day Moving Average 1.0177
20-Day Moving Average 1.0198
10-Day Moving Average 1.051
Average True Range 0.0669
ADX 14.92
+DI 15.6504
-DI 17.1053
Chandelier Exit (Long, 3 ATRs ) 0.9493
Chandelier Exit (Short, 3 ATRs ) 1.1007
Upper Bollinger Band 1.1332
Lower Bollinger Band 0.9064
Percent B (%b) 0.46
BandWidth 22.239655
MACD Line 0.0078
MACD Signal Line 0.0135
MACD Histogram -0.0057
Fundamentals Value
Market Cap 69.74 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -2.59
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.04
Resistance 3 (R3) 1.04 1.04 1.04
Resistance 2 (R2) 1.04 1.03 1.04 1.03
Resistance 1 (R1) 1.02 1.02 1.02 1.02 1.03
Pivot Point 1.02 1.02 1.02 1.02 1.02
Support 1 (S1) 1.00 1.01 1.00 1.00 0.99
Support 2 (S2) 1.00 1.00 1.00 0.99
Support 3 (S3) 0.98 1.00 0.99
Support 4 (S4) 0.98